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Variant Creutzfeldt-Jakob disease (vCJD) has been 
reported in 12 countries. We hypothesized that a common 
strain of agent is responsible for all vCJD cases, regardless 
of geographic origin. To test this hypothesis, we inoculated 
strain-typing panels of wild-type mice with brain material from 
human vCJD case-patients from France, the Netherlands, 
Italy, and the United States. Mice were assessed for clinical 
disease, neuropathologic changes, and glycoform profi le; 
results were compared with those for 2 reference vCJD 
cases from the United Kingdom. Transmission to mice 
occurred from each sample tested, and data were similar 
between non-UK and UK cases, with the exception of the 
ranking of mean clinical incubation times of mouse lines. 
These fi ndings support the hypothesis that a single strain 
of infectious agent is responsible for all vCJD infections. 
However, differences in incubation times require further 
subpassage in mice to establish any true differences in 
strain properties between cases.
Variant Creutzfeldt-Jakob disease (vCJD) is an acquired transmissible spongiform encephalopathy (TSE), 
or prion disease, that results in a fatal neurodegenerative 
condition in humans. vCJD was fi rst reported in the United 
Kingdom in 1996 (1) and was most likely caused by dietary 
exposure to contaminated products from cattle that had 
bovine spongiform encephalopathy (BSE). The similarity 
between BSE and vCJD was shown by experimental 
transmission of the 2 diseases into standard panels of 
inbred wild-type mouse lines (RIII, C57BL, and VM [1,2]) 
and into FVB mice (3).
The strain properties of vCJD and BSE have been 
extensively characterized in these sets of mice by using 
a combination of the order in which each strain of mouse 
dies of disease (incubation period rankings), distribution of 
brain vacuolation at the terminal stage of disease (lesion 
profi les), distribution pattern of abnormal prion protein 
(PrPSc) in the brain, and glycosylation pattern of PrPSc as 
assessed by Western blot analysis. BSE and vCJD produce 
highly reproducible and similar incubation period rankings 
and neuropathology, which indicates that they are the same 
strain in the RIII, C57BL, and VM mice, whereas in the 
FVB mice, both diseases exhibit the same pattern of PrPSc 
deposition (3–5).
During 1996–2011, a total of 176 cases of defi nite or 
probable vCJD were reported in the United Kingdom; the 
number of deaths peaked at 28 in 2000. Since 2006, deaths 
from vCJD have leveled off to 2–5 per year (6). Although 
vCJD was originally restricted to the United Kingdom, 49 
cases have been reported in 11 other countries, including 
some outside Europe, bringing the worldwide total 
number of cases to 225. Most cases outside the United 
Kingdom have occurred in France, which is believed to 
be related to the large volume of beef imports; ≈60% of 
UK beef exports to Europe were destined for France (7). 
This possible relationship is borne out by a peak in vCJD 
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cases in France 5 years after a similar peak in cases in the 
United Kingdom, which fi ts in well with the timing of an 
increase in beef imports from the United Kingdom during 
1985–1995 (7).
More recently, comparative studies of vCJD cases 
from France and the United Kingdom have shown evidence 
from clinical, epidemiologic, pathologic, and biochemical 
analyses that a common strain of agent may be responsible 
for vCJD infection in both countries (8). In Europe, active 
surveillance to monitor BSE cases was implemented in 
2001 (6,9). Although it appears that exports of meat, cattle, 
or both from the United Kingdom may have played a major 
role in the incidence of vCJD cases in other countries (10), 
indigenous BSE from before 2001 or another unidentifi ed 
source may have caused some vCJD infections.
To determine whether vCJD cases in different 
countries have been caused by the same infectious agent, 
samples from 4 vCJD case-patients from the Netherlands, 
Italy, France, and the United States were made available for 
strain typing analysis using a standard panel of wild-type 
mouse lines. Each sample was methionine homozygous at 
codon 129 of the prion gene (Table). None of the patients 
had received blood or organ donations. Two patients (from 
Italy and the United States) were treated with quinacrine. 
All case-patients showed classic clinical characteristics of 
vCJD; postmortem examination confi rmed the diagnosis. 
We conducted transmission studies in mice using brain 
samples from these 4 vCJD case-patients and compared 
transmission characteristics of all 4 cases to those of 2 
historical cases of vCJD in the United Kingdom.
Materials and Methods
CJD Inocula
Frozen brain tissue consisting of ≈3 g of frontal cor-
tex from each of 4 vCJD case-patients originating from 
the Netherlands, Italy, France, and the United States was 
available for transmission studies (Table). An additional 
similar sample of cerebellum from the vCJD case-patient 
from Italy was also studied to assess any differences in 
transmission characteristics between different regions of 
the brain. Tissue samples were homogenized at 10% (wt/
vol) concentration in sterile physiologic saline and stored 
at −20°C until use. Ethical consent for the use of these 
materials for research was obtained and approved by the 
Lothian National Health Service Board Research Ethics 
Committee (reference: 2000/4/157).
Experimental Animals
Two lines of mice expressing Prn-pa (RIII, C57BL) 
and 1 line expressing Prn-pb (VM) were used for the 
transmission experiments. The Prn-pa and Prn-pb alleles 
have a major infl uence on the incubation period of disease, 
with each TSE strain having a distinct and reproducible 
incubation period ranking with each of the Prn-p genotypes 
(11). Mice were anesthetized with halothane and inoculated 
with brain homogenate by a combination of intracerebral 
(i.c.) (0.02 mL) and intraperitoneal (0.1 mL) routes to 
ensure effi cient uptake of the agent. Because the quantity 
of material available was limited, mice received only i.c. 
inoculations (0.02 mL) from the case-patient from the 
United States.
Mice were scored weekly for signs of clinical 
neurologic disease from 100 days as described by 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 10, October 2012 1575
Table. Demographic and clinical features of case-patients with variant CJD from the Netherlands, France, Italy, and United States and 
2 reference case-patients from the United Kingdom* 
Characteristic
The
Netherlands France Italy 
United
States
United Kingdom 
1 2 
Case-patient sex F F F F M M 
Case-patient age at illness onset, y 24 36 25 22 24 35 
Case-patient age at death, y 26 37 27 24 25 36 
Disease duration, mo 19 14 27 32 14 12 
Early psychiatric symptoms Yes Yes Yes Yes Yes Yes 
Persistent painful sensory symptoms Yes No Yes No Yes No 
Ataxia Yes Yes Yes Yes Yes Yes 
Myoclonus, dystonia, or chorea Yes Yes Yes Yes Yes Yes 
Dementia Yes Yes Yes Yes Yes Yes 
No typical appearance of sporadic CJD on EEG Yes Yes No Yes Yes Yes 
Bilateral symmetric pulvinar high signal on MRI scan 
of brain 
Yes No Yes Yes Yes No 
Positive tonsil biopsy result ND Yes Yes Yes ND ND 
Treatment No specific 
treatment 
No specific 
treatment 
Quinacrine Quinacrine No specific 
treatment 
No specific 
treatment 
History of travel to or residence in the United 
Kingdom
No No No Yes† Yes Yes 
Codon 129MM Yes Yes Yes Yes Yes Yes 
Type 2B PrP Yes Yes Yes Yes Yes Yes 
*CJD, Creutzfeldt-Jakob disease; EEG, electroencephalogram; MRI, magnetic resonance imaging; ND, not done; PrP, prion protein. 
†Born in United Kingdom in 1979, moved to United States in 1992. 
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Fraser and Dickinson (12). Mice were killed by cervical 
dislocation whether due to TSE or other nonspecifi c disease 
and the brain removed at postmortem. Brains were cut 
sagitally; half was snap-frozen for biochemical analysis, 
and the remaining half was fi xed in 10% formol saline for 
histologic analysis. Experiments were approved by The 
Roslin Institute’s Ethical Review committee and were 
conducted according to the regulations of the UK Home 
Offi ce Animals (Scientifi c Procedures) Act 1986.
Scoring of Vacuolation
After fi xation, mouse brains were treated for 1.5 hours 
in 98% formic acid to reduce the infective titer for safety 
reasons. Brains were then cut transversely into 4 sections 
(hind brain, midbrain, forebrain, and hippocampus/
thalamus) and embedded in paraffi n. Samples underwent 
hematoxylin and eosin staining, and each mouse was 
scored for degree of vacuolation (ranked 1–5, with 1 the 
least affected) found in 9 standard gray matter regions and 
3 white matter regions. Scores for >6 mice were averaged 
to produce a mean lesion profi le for each of these areas 
(12).
PrP Immunohistochemical Analysis
Paraffi n-embedded tissue sections were pretreated 
to aid antigen retrieval by autoclaving for 10 min at 
121°C. Sections were then immersed in formic acid for 
10 min to enhance PrP labeling. PrP immunostaining was 
performed by using the monoclonal anti-PrP antibody 6H4 
(Prionics, Schlieren-Zurich, Switzerland) at a dilution of 
1:10,000 overnight at room temperature. The secondary 
antibody was biotinylated rabbit anti-mouse (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, 
USA) used at 1:400 for 1 h. The Vectastain Elite ABC 
Kit (Vector Laboratories, Burlingame, CA, USA) was 
used, and visualization of antibody binding was through 
deposition of 3,3′-diaminobenzidine chromogen.
Western Blot Analysis of PrPSc
Frozen brain samples were homogenized in 0.9% 
saline solution to yield a 10% suspension. This material 
was cleared by centrifugation and the supernatant treated 
with 50 μg/mL proteinase K for 1 h at 37°C (for detailed 
methods, see Head et al. [13]). The digested product 
was denatured and then loaded onto a 10% Bis/Tris 
NuPAGE Novex gel (Invitrogen, Paisley, UK). After 
electrophoresis, the gel was blotted onto polyvinylidene 
fl uoride membranes. Detection of prion protein used the 
enhanced chemiluminescence ECL+ technique (Amersham 
Biosciences, Little Chalfont, UK) with primary antibody 
6H4 at 1:30,000 and an anti-mouse IgG peroxidase-linked 
secondary antibody (Amersham Biosciences) at 1:60,000. 
Images were captured on radiographic fi lm.
Results
All 5 vCJD brain isolates transmitted successfully to 
the wild-type mouse panel with the appearance of clinical 
and pathologic signs associated with prion disease. Mean 
incubation periods and mouse line ranking order were 
calculated and compared with reference data from the 
United Kingdom. The inocula from the Netherlands, Italy 
(cortex and cerebellum), and the United States showed 
variation in the temporal order of appearance of clinical 
symptoms in each of the mouse strains when compared with 
the UK reference cases (Figure 1). These 3 brain inocula 
showed the shortest incubation periods in the RIII mice, 
occurring at ≈365 days postinoculation (dpi), followed by 
VM at ≈450 dpi; the longest was found in the C57BL mice 
(≈465 dpi). The ranking of incubation time differed with 
brain inocula from France, with the C57BL mice dying of 
disease before the VM mouse line, similar to the pattern 
observed in the UK reference cases. The exact timing of the 
appearance of clinical symptoms varied, with wide ranges 
observed for each line of mouse within and between the 
different inocula; incubation periods were 301–463 days in 
RIII mice, 361–553 days in VM mice, and 335–553 days 
in C57BL mice.
Lesion Profi les
Suffi cient numbers of wild-type mice scored positive 
for the presence of TSE-associated vacuolation to enable 
lesion profi les to be generated from their mean scores. 
Similar patterns of vacuolation distribution were seen for 
all vCJD isolates, including those taken from either the 
cortex or cerebellum (case-patient from Italy) (Figure 2). 
Mouse strains of the same PrP genotype showed close 
similarities in lesion profi les with Prn-pa mice (RIII and 
C57BL), showing moderate gray matter vacuolation of the 
medulla, hypothalamus, and septum, with C57BL mice 
additionally exhibiting mild white matter vacuolation of 
the basal cerebellar peduncle. Prn-pb mice (VM) showed 
mild to moderate gray matter vacuolation of the medulla, 
superior colliculus, thalamus, and septum. Some variability 
was found in the intensity of vacuolation dependent on the 
vCJD isolate, most notably in the VM mice and particularly 
in the superior colliculus, hypothalamus, and thalamic 
regions.
Immunohistochemical Analysis of PrP
A total of 9 mice per inoculum, corresponding to 3 
animals per genotype, were analyzed in a blinded experiment 
design. Animals from each group showed variability in 
the amount of PrP accumulation (Figure 3). Fine punctate 
deposits were the most consistently observed pattern of 
PrP accumulation in mice from all genotypes. However, 
in numerous instances, PrP plaques were also seen in the 
corpus callosum and subventricular area and, eventually, in 
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the brain parenchyma of the cerebrum and cerebellum. VM 
mice showed a similar pattern of PrP deposition with each 
inoculum and consistently showed PrP plaques. RIII mice 
appeared to show less staining with the accumulation of 
PrP forming fi ne punctate, coarse, pericellular, and plaque 
deposits. In the C57BL line, PrP deposition appeared more 
variable within and between inocula.
Biochemical Analysis of PrP
Biochemical analysis of PrPSc by Western blot produced 
a type 2B–like gel mobility and glycosylation profi le in 
all mouse strains (Figure 4). This profi le is characterized 
by the predominance of the diglycosylated form of PrPSc 
and an ≈19-kDa unglycosylated fragment, similar to that 
seen in all vCJD human brain tissue examined to date. 
The unglycosylated fragment appeared as a doublet with a 
distinct upper and lower band and the relative intensity of 
the 2 bands varying with mouse Prn-p genotype; the lower 
band appeared more intense in Prn-pa mice and the higher 
band more intense in Prn-pb mice. The biochemical profi le 
was identical for all 5 brain isolates and identical to the 
pattern observed in the UK cases.
Discussion
We used transmission studies with wild-type mice to 
defi ne the strain characteristics of geographically distinct 
cases of vCJD to establish whether a common strain 
of agent is responsible for vCJD cases from 5 different 
countries. Transmission properties such as TSE-associated 
vacuolation, PrPSc deposition, glycosylation profi le, and 
mobility of PrP all show strong similarities between vCJD 
cases from the Netherlands, Italy, France, and the United 
States and with reference cases from the United Kingdom.
The distribution of TSE vacuolation and PrPSc 
deposition in the brains of the RIII and VM mice was similar 
for each brain isolate examined and indicates that the same 
strain of agent is present in each inoculate. C57BL mice 
showed more variability in PrPSc deposition, which may 
be a result of the transmission of the vCJD agent across 
a species barrier. Each brain isolate produced a type 2B–
like glycoform profi le on biochemical analysis; similar to 
results from previous studies, the unglycosylated fragment 
appeared as a doublet (14).
We observed differences in the timing of the onset of 
clinical signs of disease for each of the non-UK cases, which 
may be because of differences in the infectious titer of the 
different vCJD isolates. We also identifi ed a change in the 
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Figure 1. Comparison of variant Creutzfeldt-Jakob disease 
incubation periods from 5 sources in wild-type mice. Data 
show mean incubation period ± SEM. i.c., intracerebral; i.p., 
intraperitoneal; UK, United Kingdom.
Figure 2. Lesion profi le comparison of variant Creutzfeldt-Jakob 
disease cases show similarities in vacuolar pathology levels and 
regional distribution in mouse brains. Wild-type mouse lines RIII 
(A), C57 (B), and VM (C) are shown. Data show mean lesion 
profi le ± SEM (n>6). G1–G9, gray matter scoring regions: G1, 
dorsal medulla; G2, cerebellar cortex; G3, superior colliculus; G4, 
hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, 
retrosplenial and adjacent motor cortex; G9, cingulate and adjacent 
motor cortex. W1–W3, white matter scoring regions: W1, cerebellar 
white matter; W2, mesencephalic tegmentum; W3, pyramidal tract.
RESEARCH
incubation period ranking of the mouse strains between the 
inoculum from France and other locations (Figure 1). For 
each brain isolate, the RIII mice were the fi rst line to die of 
disease, consistent with previous transmissions from vCJD 
cases in the United Kingdom.
Furthermore, our study has shown that the ≈100-
day difference in incubation period between the RIII and 
C57BL mice (both Prn-pa), which is characteristic of 
the BSE strain, has been maintained in the experimental 
transmission of the vCJD worldwide cases (15). The C57BL 
and VM mice have resulted in close incubation period 
ranges that can overlap, as was demonstrated previously 
(14,15). For inocula from the non-UK cases, incubation 
periods appeared in the order RIII, VM, C57BL, whereas 
the inocula from France showed incubation periods in the 
order RIII, C57BL, VM, as do the historic UK cases. This 
change in the order could be attributed to genetic drift in 
the mouse lines used over the course of the historical and 
current studies or variations in the strain of TSE agent.
The VM mice used in this study have shown 
substantially shortened incubation periods compared with 
those from in earlier studies, which may have caused the 
alteration in ranking. This alteration in incubation time 
ranking was also identifi ed recently in a comparable 
transmission study involving a more recent UK vCJD case 
(M. Bishop et al., unpub. data). Moreover, the difference 
in time ranking is unlikely to be attributable to variation 
in brain area; we have established similar transmission 
characteristics between brain regions and have aimed 
in this study to use identical brain regions for each non-
UK case. Differences in inoculation route are also not 
an explanation for the alteration in ranking. Differences 
were not found between the case from the United States, 
which was inoculated i.c. only, and the cases from the 
Netherlands and Italy, which were inoculated i.c. and 
intraperitoneally.
The infectivity titer of the inoculum may have played 
a role in alteration of the incubation periods. However, 
Ritchie et al. (14) suggested that changes in titer would 
affect all mouse strains and would not result in a change in 
the ranking of the mouse strains. Experimental transmission 
of vCJD from the case from the United States, in which 
lower volumes were inoculated, shows the same temporal 
pattern as the cases from the Netherlands and Italy.
Variability in incubation time is often associated with 
the primary transmission of a TSE agent between species 
but often stabilizes on subsequent mouse-to-mouse passage, 
while variability within groups decreases. Therefore, 
variations observed in this study do not necessarily point 
to strain variation between the cases of vCJD. However, 
to rule out this possibility, further transmission studies 
will be conducted. Moreover, passage of cases of vCJD 
occurring during the past 15 years will be undertaken in 
a comparative study to establish whether genetic drift 
in mouse lines or strain variation in vCJD underlies the 
differences observed in this study. Two of the brain isolates 
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Figure 3. Immunohistochemical detection of abnormal prion protein 
(PrPSc) in the hippocampus and thalamus of RIII, C57, and VM wild-
type mice after inoculation with variant Creutzfeldt-Jakob disease 
brain tissue. Scale bars = 500 μm. The anti–prion protein detection 
antibody used was 6H4.
Figure 4. Western blot analysis of brain extracts from RIII (A) and 
VM (B) wild-type mice inoculated with variant Creutzfeldt-Jakob 
disease (vCJD) brain tissue. Lane M, positive control; lane 1, human 
vCJD brain homogenate (UK origin) showing the typical abnormal 
prion protein (PrPSc) type 2B; lane 2, United Kingdom; lane 3, The 
Netherlands; lane 4: Italy (cortex); lane 5, Italy (cerebellum); lane 6, 
France; lane 7, United States; lane 8, human sporadic Creutzfeldt-
Jakob disease brain homogenate showing the typical PrPSc type 1. 
Type 2B and 1 differ in mobility of the unglycosylated band (≈19 kDa 
and ≈20 kDa, respectively). All samples were treated with proteinase 
K. The anti–prion protein detection antibody used was 6H4.
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inoculated (from Italy and the United States) were from 
patients who had been treated with quinacrine. However, 
this treatment appears to have had no effect on incubation 
periods, vacuolation profi les, PrPSc deposition patterns, or 
the glycosylation and mobility of PrP.
The similarities in lesion profi les, biochemistry, 
and immunohistochemistry between this series of vCJD 
transmission studies support the hypothesis that a single 
strain of infectious agent is responsible for all vCJD cases, 
regardless of geographic origin, which would suggest that 
current diagnostic criteria for vCJD are suffi cient to detect 
cases in all countries at this time. Still to be determined 
is whether the differences in incubation period rankings 
in some cases represent changes in strain phenotype over 
time, which could affect future diagnosis.
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